Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States
Authors:
- Jeffrey S. BorerJBJeffrey S. Borer
- Anuraag R. KansalAKAnuraag R. Kansal
- Emily D. DormanEDEmily D. Dorman
- Stanimira KrotnevaSKStanimira Krotneva
- Ying ZhengYZYing Zheng
- Harshali K. PatelHPHarshali K. Patel
- Luigi TavazziLTLuigi Tavazzi
- Michel KomajdaMKMichel Komajda
- Ian FordIFIan Ford
- Michael BöhmMBMichael Böhm
- Adrian KielhornAKAdrian Kielhorn
- 1 September 2016
- journal article
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 22 (9) , 1068-1075
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT studyClinical Research in Cardiology, 2012
- Atrial Fibrillation and Mortality in Heart FailureCirculation: Heart Failure, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trialThe Lancet, 2008
- Resting Heart Rate in Cardiovascular DiseaseJACC, 2007
- Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2006
- Trends in Heart Failure Incidence and Survival in a Community-Based PopulationJAMA, 2004
- Lifetime Risk for Developing Congestive Heart FailureCirculation, 2002